Highlights from Ayrton Drug’s Annual Report- Chairman’s Letter
The Chairman said 2012 was a tough year for the company. Top-line (Sales) grew by 14.68% but the bottom-line ( Profit after tax) fell by 13.61%. This he attributed to the depreciating cedi and astronomical increases in interest rates, among other factors.
Earnings per share fell from 0.0133p in 2011 to 0.0115 in 2012 whiles dividend per share remained at 0.125p
Plans are far advanced to build a new facility in a bid to improve the bottom line. There would also be restructuring of the company to increase efficiency of all the Departments.